Form 8-K - Current report:
SEC Accession No. 0000950170-25-042647
Filing Date
2025-03-20
Accepted
2025-03-20 16:06:22
Documents
15
Period of Report
2025-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rkda-20250320.htm   iXBRL 8-K 55540
2 EX-99.1 rkda-ex99_1.htm EX-99.1 75428
3 EX-99.2 rkda-ex99_2.htm EX-99.2 431342
4 GRAPHIC img192114479_0.jpg GRAPHIC 9353
5 GRAPHIC img193038000_0.jpg GRAPHIC 9353
  Complete submission text file 0000950170-25-042647.txt   730298

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rkda-20250320.xsd EX-101.SCH 24852
17 EXTRACTED XBRL INSTANCE DOCUMENT rkda-20250320_htm.xml XML 4670
Mailing Address 202 COUSTEAU PLACE SUITE 105 DAVIS CA 95618
Business Address 202 COUSTEAU PLACE SUITE 105 DAVIS X1 95618 530-756-7077
Arcadia Biosciences, Inc. (Filer) CIK: 0001469443 (see all company filings)

EIN.: 810571538 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37383 | Film No.: 25756472
SIC: 1311 Crude Petroleum & Natural Gas
(CF Office: 01 Energy & Transportation)